X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Grifols and the European Investment Bank sign an Euros 85 million long-term loan to support its R+D+i initiatives

Yuvraj_pawp by Yuvraj_pawp
5th December 2017
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The European Investment Bank (EIB) and Grifols signed an Euros 85 million loan to support the company’s R+D+i initiatives focused on investigating new indications for plasma-derived protein therapies to treat rare and chronic diseases. The agreement is backed by the European Fund for Strategic Investments (EFSI). The EFSI is the central pillar of the Investment Plan for Europe, commonly known as the “Juncker Plan”.

The loan offers several favorable financial conditions, including a fixed interest rate, maturity date in 2027 and a two-year grace period.

The loan agreement will strengthen Grifols research efforts aimed at improving the health and quality of life of patients, as well as drive innovation in the medical-research field throughout the European Union. Moreover, it will contribute to fostering high-skill employment and bioscientific research within the network of universities, hospitals and research centers that collaborate with Grifols.

The agreement represents the second EIB loan conceded to Grifols under the umbrella of the Investment Plan for Europe, following the first one signed in 2015 when Grifols became one of the first European companies to receive funding from the Juncker Plan. With this second loan, the company builds on its positive initial experience and consolidates its relationship with the institution, which it highly values as a complementary source of funding for its

R+D+i projects.
As a leading-edge innovator in the global healthcare sector, Grifols channels substantial resources toward both in-house and external R+D+i projects. As of September 30, 2017, the company had allocated Euros 201.6 million in net investments in R+D+i, denoting a 23.8% increase compared to the same period last year. This upward trend in research spending is a clear testament to the company’s efforts in this area.

About the European Investment Bank and the “Juncker Plan”
The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It makes long-term financing available for sound investments to contribute towards EU policy goals.

The Investment Plan for Europe, known as the “Juncker Plan,” is one of the European Commission’s top priorities. It centers its efforts on promoting investments that spur job creation and economic growth through a more intelligent use of new and existing financial resources. At the same time, it aims to eliminate investment obstacles, and offer better visibility and technical assistance to EU investment projects.

The European Fund for Strategic Investments (EFSI) is the main pillar of the “Juncker Plan.” By offering guarantees for first losses, the EFSI enables the EIB to increase its investments in projects that traditionally carry a higher degree of risk. The EFSI’s efforts have already translated into tangible results. According to forecasts, the projects and agreements approved for funding within the EFSI framework will mobilize more than Euros 250 billion in investments, and support the approximately 528,000 SMEs currently operating in the 28 Member States.

Previous Post

Sunovion Receives FDA Approval for Lonhalaâ„¢ Magnairâ„¢ Inhalation Solution to Treat COPD

Next Post

AMPEL BioSolutions, Horizon Pharma plc, and Lupus Research Alliance Partner on Unique Clinical Trial for Patients with Lupus

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post

AMPEL BioSolutions, Horizon Pharma plc, and Lupus Research Alliance Partner on Unique Clinical Trial for Patients with Lupus

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In